

Please make the following amendments to the claims:

1. (currently amended) A method of treating pathogenic polyclonal B cell activation or class switching in a patient, the method comprising:

administering to said patient an effective dose of a CD1 blocking antibody or fragment of an antibody thereof, wherein said antibody or fragment thereof binds to CD1, and interferes with T cell recognition of CD1;

wherein said dose is effective to treat reduce the pathogenic symptoms of said polyclonal B cell activation or class switching.

2. (original) The method according to Claim 1, wherein said pathologic polyclonal B cell activation or class switching results in systemic lupus erythematosus.

3-5. (canceled)

6. (previously presented) The method according to Claim 1, wherein said antibody is a monoclonal antibody.

7. (original) The method according to Claim 6, wherein said monoclonal antibody is a human or humanized antibody.

8. (previously presented) The method according to Claim 6, wherein said monoclonal antibody specifically binds to human CD1d.

9. (canceled)

10. (previously presented) The method according to Claim 6, wherein said antibody comprises a cocktail of monoclonal antibodies that bind to multiple human CD1 isotypes.

11. (canceled)

12. (original) The method according to Claim 2, wherein said administration is by intravenous injection.

13. (previously presented) A method according to Claim 2, further comprising administering to said patient a second therapeutic agent which is an immunosuppressant, anti-inflammatory, or anti-coagulant agent for the treatment of systemic lupus erythematosus.

14. (canceled)